BIIB Articles, Biogen Inc. - From 04/24/24

On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The...

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semi...

As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...

Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation...

The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company...

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Comp...

Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...

New data advances understanding of new approaches to treating Alzheimer's disease Research on disease progression could help inform future c...

NEW YORK, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigati...

Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y ...